stockportfolio.pro
Stocks / CDNA vs KMTS
CDNA vs KMTS
CareDx, Inc. and Kestra Medical Technologies, Ltd. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| CareDx, Inc. (CDNA) | Kestra Medical Technologies, Ltd. (KMTS) | |
|---|---|---|
| Market cap | $1.2B | $1.2B |
| Revenue (latest FY) | $379.81M | $59.81M |
| Net income (latest FY) | $-21.35M | $-113.81M |
| Revenue growth (5y CAGR) | 14.6% | 180.0% |
| Net margin | -5.6% | -190.3% |
| Return on equity | -7.0% | -55.4% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CDNA — free Open KMTS — freeFrequently asked questions
Which is bigger, CDNA or KMTS?
CareDx, Inc. is larger by market capitalization — $1.2B versus $1.2B.
Which grows faster, CDNA or KMTS?
Over the last five fiscal years, Kestra Medical Technologies, Ltd. grew revenue faster — 180.0%/yr versus 14.6%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.